retatrutide phase 2 nejm 2023 obesity trial jastreboff Michael Weintraub, MD on X: "Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight ๐FAT LOSS WITH Retatrutide.. .
Pay in 4 interest-free payments of $7.19 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours ยท Estimated delivery Aug 14 - Aug 19



























